Top Abstract Purchase Related
Home
>
Node
>
Subnode

Preliminary experience with achieving immune tolerance in patients with hemophilia a and circulating factor VIIi inhibitor

Scharf, R.; Kucharski, W.; Lopaciuk, S.; Celińska, W.; Dmytrow, A.; Domański, K.; Gonet, S.; Miastkowski, Z.; Nowakowska, I.; Przybylski, A.

Acta Haematologica Polonica 22(1): 92-99

1991

ISSN/ISBN: 0001-5814
PMID: 1823972
Document Number: 376369
The appearance of antibodies to factor VIII is a serious complication in the treatment of haemophilia A. A protocol is presented aiming at suppression of the anticoagulant using continued treatment with factor VIII (25 u/kg b.w. twice weekly). Ten patients with previous maximal factor VIII antibody titre from 7 to 2900 Bethesda units were treated. So far the inhibitor was eradicated in 3 cases treated continuously for from 5 to 20 months. In two of these three cases successful surgical procedures were performed without anamnestic response.

Document emailed within 1 workday
Secure & encrypted payments

Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68
Landolfi, R.; de Cristofaro, R.; Lazzareschi, I.; Riccardi, R.; Mariani, G. 2000: Immune tolerance by intermittent factor VIIi boluses in two high responder hemophilia a patients Haematologica 85(10 Suppl): 73-74
DiMichele, D.; Kroner, B. 2000: The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis Haematologica 85(10 Suppl): 40
Ambriz-Fernández, R.; Reyna-Fregoso, M.P.; Pizzuto-Chávez, J.; Rodríguez-Moyado, H.; Farfán-Canto, J.M.; Trueba-Christy, E.; Collazo-Jaloma, J. 1985: Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. a study of the cooperative group of hemophilia Archivos de Investigacion Medica 16(3): 225-235
Pfyffer, M.; Kistler, H.J.; von Felten, A. 1983: Acquired hemophilia a due to factor VIIIC inhibitor: detection of circulating immune complexes containing factor VIIIC but not factor VIIIR Schweizerische Medizinische Wochenschrift 113(40): 1456-1459
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Schoppmann, A.; Waytes, A.T. 1996: Factor VIIi inhibitor and severity of hemophilia Thrombosis and Haemostasis 76(2): 280-281
Davis, H.M.; Brown, S.K.; Nash, D.W.; Pennetti, A.M.; Salzman, P.M.; Schreiber, A.B.; Haimovich, J. 1990: Lack of immune response to mouse IgG in hemophilia a patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIIi preparation Thrombosis and Haemostasis 63(3): 386-391
Hoyer, L.W.; Qian, J. 2000: Characterization of the immune response to factor VIIi using hemophilia A* mice Haematologica 85(10 Suppl): 100-102
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302
Vianello, F.; Tison, T.; Tagariello, G.; Zerbinati, P.; Zanon, E.; Scarano, L.; Girolami, A. 1999: Serological markers of autoimmunity in patients with hemophilia A: the role of hepatitis C virus infection, alpha-interferon and factor VIII treatment in skewing the immune system toward autoreactivity Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 10(6): 393-397
Reipert, B.M.; Schwarz, H.P. 2002: What can we learn from the immune response to human factor VIIi in a mouse model of hemophilia A? Thrombosis and Haemostasis 88(2): 374-375
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Gomperts, E.D.; Jordan, S.; Berg, D.; Sakai, R.; Boylen, L. 1981: Circulating immune complexes pre and post clotting factor infusion in hemophilia Thrombosis and Haemostasis 46(4): 694-698
Scheibel, E.; Ingerslev, J.; Dalsgaard-Nielsen, J.; Stenbjerg, S.; Knudsen, J.B. 1987: Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated Thrombosis and Haemostasis 58(4): 1049-1052
Mariani, G.; Hilgartner, M.; Thompson, A.R.; Tusell, J.; Manco-Johnson, M.; Ghirardini, A.; Bellocco, R.; Brackmann, H.H. 1995: Immune tolerance to Factor VIII: the international registry data Advances in Experimental Medicine and Biology 386: 201-208
Brakman, G.G. 1993: The occurrence of immunological tolerance to inhibitors of factors VIIi and IX in hemophilia patients Gematologiia i Transfuziologiia 38(2): 18-20
Lopaciuk, S.; Ziemski, J.M. 1979: Treatment of patients with hemophilia a having antibodies to factor VIIi Acta Haematologica Polonica 10(2): 115-122
Riera, N.E.; de Bracco, M.M. 1987: Circulating immune complexes and fibronectins in patients with hemophilia Medicina 47(4): 440-441